Are you Dr. Himelstein?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 87 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4701 Ogletown Stanton Rd
Ste 3400
Newark, DE 19713Phone+1 302-366-1200Fax+1 302-366-1700
Summary
- Dr. Andrew Himelstein, MD is an oncologist in Newark, Delaware. He is currently licensed to practice medicine in Delaware, New Jersey, and Pennsylvania. He is affiliated with ChristianaCare and St. Francis Hospital.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1988 - 1991
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1985 - 1988
Washington University in St. Louis School of MedicineClass of 1985
Certifications & Licensure
DE State Medical License 1991 - 2025
PA State Medical License 1991 - 2024
NJ State Medical License 1991 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Fellow (FACP) American College of Physicians, 1998
Clinical Trials
Publications & Presentations
PubMed
- 91 citationsFeasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Lori M. Minasian, William Kevin Kelly
JAMA Oncology. 2017-08-01 - 43 citationsThe BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor geneEric S. Martin, Rossano Cesari, Francesca Pentimalli, Kristine E. Yoder, Richard Fishel
Proceedings of the National Academy of Sciences of the United States of America. 2003-09-30 - 43 citationsCost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALG...Charles L. Shapiro, James P. Moriarty, Stacie B. Dusetzina, Andrew L. Himelstein, Jared C. Foster
Journal of Clinical Oncology. 2017-10-12
Press Mentions
COMMENTARY: Start the Conversation with Your DoctorFebruary 17th, 2019
Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients with Bone MetastasesJanuary 8th, 2017
Powerful Drug for Advanced Cancers May Need Less Frequent DosingJanuary 4th, 2017
Professional Memberships
- Member
- Fellow
